Résumé

P162

Vitamin D intake and light chain-IgG monoclonal antibodies in patients with multiple myeloma

Dr. Mourad ARIBIa, Mme Samira SENOUCI-BEREKSIa, Dr. Mustapha HADDOUCHEa, Pr. Naima MESLIb

a Laboratory of Applied Molecular Biology and Immunology, b Laboratory of Applied Molecular Biology and Immunology and Haematology Department of Tlemcen Medical Centre University

Objectives: To estimate the average daily vitamin D intake and to determine the type and levels of light chain-IgG monoclonal antibodies in patients with multiple myeloma (MM).

Patients and Methods: A total of 52 subjects divided into three groups (Groups 1; n = 19 patients with MM [10 males, 9 females], Group 2; n = 13 relative controls [9 males, 4 females], Group 3; n = 20 unrelated controls [11 males, 9 females]) were recruited at the Hematology Department of Tlemcen University Medical Center (Algeria). Nutritional survey was conducted over a period of one month through a diet history interview, based on the 24-hour recall. The characterization of monoclonal antibodies was performed by serum immunofixation test on Hydragel IF K20 (Sebia, France).

Results: The vitamin D intake was slightly lower in patients as compared to unrelated controls and was associated with risk of developing MM (OR = 2.08). Additionally, the frequency of IgG-kappa band was significantly higher than that of IgG lambda-band.

Discussion: Vitamin D could be considered as an effective prognostic factor and treatment of MM, especially in patients with monoclonal IgG kappa immunoglobulin.

Keywords : multiple myeloma, light chain-IgG monoclonal antibodies, vitamin D intake